Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mechanisms of Response to Diesel Exhaust in Subjects With Asthma

6. april 2017 oppdatert av: University of Pennsylvania
In a controlled exposure setting, the study's goal is to determine the acute effect of diesel exhaust (DE) inhalation on airway inflammation and hyperresponsiveness (AHR) in subjects with mild to moderate stable asthma, using non-invasive measures.

Studieoversikt

Status

Tilbaketrukket

Forhold

Detaljert beskrivelse

The investigators will also characterize selected polymorphisms in glutathione-S-transferase (GST) genes that have been implicated in susceptibility to air pollutants. Outcome measures will include lung function, bronchial responsiveness to bronchodilator, exhaled nitric oxide, induced sputum for inflammatory markers (IL6 and IL8), and exhaled breath condensate for nitrite, 8-isoprostane, 20-HETE (20-hydroxyeicosatetraenoic acid), nitrotyrosine and pH.

In this pilot project, parallel studies are being carried out in the human exposure chambers at two NIEHS centers, the EOHSI-CEED (Environmental and Occupational Health Sciences Institute- Center for Environmental Exposure and Disease) and the Penn-CEET (University of Pennsylvania-Center of Excellence in Environmental Toxicology). The joint project will enable each center to validate research results in a second population and include new biomarkers of pulmonary inflammation. Each center will recruit, consent, and collect data on its own subjects. Only de-identified data will be shared between the centers.

Studietype

Observasjonsmessig

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Pennsylvania
      • Philadephia, Pennsylvania, Forente stater, 19104
        • Airways Biology Initiative at Penn Presbyterian Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 55 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

All subjects will have been verified to meet criteria for mild/moderate asthma. At the same time all subjects will have been verified to be able to produce adequate sputum plugs for analysis.

Beskrivelse

Inclusion Criteria:

  1. Subject is an adult male or female between 18 and 55 years of age inclusive.
  2. Subject must have a prior history of a physician's diagnosis of asthma with reversible airway obstruction (shown by a greater than 12% increase in FEV1 following bronchodilator; or a positive methacholine challenge done following the screening visit. If methacholine challenge is required for qualification, a physician will be on-site for the test. Subject's asthma has been stable for the past six months with no change in asthma therapy.
  3. The subject has been a non-smoker for the past year and should have less than a 10-pack year history.
  4. Subject must be free of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, interstitial lung disease and bronchopulmonary dysplasia.
  5. The subject must be capable of and willing to provide written informed consent.
  6. The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
  7. The subject has no significant DE exposure that would include occupations such as truck driver, heavy equipment operator and railroad maintenance.

    -

Exclusion Criteria:

  1. As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
  2. The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives or twice the duration of the biological effect of any drug (whichever is longer) prior to the current study.
  3. Oral steroids within the last 6 months.
  4. Less than 12% FEV1 response to bronchodilator or negative methacholine challenge.
  5. Hospital admission for asthma in past 6 months.
  6. The subject has a history of alcohol or drug abuse within the last 5 years.
  7. The subject has history of hepatitis B, hepatitis C or HIV virus.
  8. The subject has a history of cardiovascular disease including hypertension or says yes to one of the cardiovascular risk questions on the screening questionnaire.
  9. The subject has a history of diabetes.
  10. The subject is pregnant or lactating.
  11. The subject has daily exposure to DE, i.e., trucking or heavy machine operators.

    -

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
FEV1 response to bronchodilator, following DE compared with filtered air (primary outcome)
Tidsramme: Up to 3 weeks
Up to 3 weeks

Sekundære resultatmål

Resultatmål
Tidsramme
Exhaled nitric oxide
Tidsramme: Up to 3 weeks
Up to 3 weeks
8-isoprostane in exhaled breath condensate
Tidsramme: 1 year
1 year
Nitrite in exhaled breath condensate
Tidsramme: 1 year
1 year
pH in exhaled breath condensate
Tidsramme: 1 year
1 year
20-HETE(20-hydroxyeicosatetraenoic acid)levels in exhaled breath condensate
Tidsramme: 1 year
1 year
Cell differential in induced sputum
Tidsramme: 1 year
1 year
Glutathione-S-transferase (GST)polymorphisms
Tidsramme: Visit 1
Visit 1
Peak Flow
Tidsramme: Up to 3 weeks
Up to 3 weeks
Forced Vital Capacity (FVC)
Tidsramme: Up to 3 weeks
Up to 3 weeks
FEV1/FVC ratio
Tidsramme: Up to 3 weeks
Up to 3 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Reynold A Panettieri, Jr., MD, UNIVERSITY of PENNSYLVANIA

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. mars 2013

Primær fullføring (Faktiske)

1. desember 2015

Studiet fullført (Faktiske)

31. desember 2015

Datoer for studieregistrering

Først innsendt

12. februar 2013

Først innsendt som oppfylte QC-kriteriene

25. februar 2013

Først lagt ut (Anslag)

27. februar 2013

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. april 2017

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. april 2017

Sist bekreftet

1. april 2017

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere